Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 17/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 16/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16972351 | 0.88 | F11 (0.41) | F11KLKB1CYP3A4 | |
| SCHEMBL16971694 | 0.87 | NOTUM (0.37) | F11KLKB1CYP3A4NOTUMP2RX7 | |
| Bromide SCHEMBL16974640 | 0.86 | NOTUM (0.36) | F11KLKB1CYP3A4NOTUMP2RX7 | |
| Bromide SCHEMBL29491785 | 0.86 | NOTUM (0.36) | F11KLKB1CYP3A4NOTUMP2RX7 | |
| SCHEMBL18316524 | 0.85 | F11 (0.37) | F11KLKB1CYP3A4NOTUM | |
| SCHEMBL16971384 | 0.85 | NOTUM (0.38) | F11KLKB1CYP3A4NOTUMKCNH2 | |
| SCHEMBL16971407 | 0.85 | F11 (0.35) | F11KLKB1CYP3A4NOTUMKCNH2 | |
| SCHEMBL30271789 | 0.84 | NOTUM (0.55) | NOTUMP2RX7KCNH2 | |
| SCHEMBL16971533 | 0.84 | NOTUM (0.41) | F11KLKB1CYP3A4NOTUMP2RX7 | |
| SCHEMBL16971551 | 0.84 | NOTUM (0.55) | NOTUMP2RX7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3099686-B1 | MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-03-11 | — | — | EP | disclosed |
| US-9777001-B2 | Macrocycles with aromatic P2′ groups as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170096429-A1 | MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-06 | — | — | US | disclosed |
| EP-3099686-A1 | MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-12-07 | — | — | EP | disclosed |
| WO-2015116885-A1 | MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096429-A1 | MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F2 | F11 6/4885KLKB1 19/4885CYP3A4 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.